Interbody fusion in degenerative lumbar spinal stenosis with additional posterolateral fusion using Escherichia coli-derived bone morphogenetic protein-2: A Pilot study
- PMID: 32541470
- PMCID: PMC7302626
- DOI: 10.1097/MD.0000000000020477
Interbody fusion in degenerative lumbar spinal stenosis with additional posterolateral fusion using Escherichia coli-derived bone morphogenetic protein-2: A Pilot study
Abstract
This case series investigated the efficacy and optimal dose of Escherichia coli-derived bone morphogenetic protein-2 (E.BMP-2) as a bone graft substitute for additional posterolateral spinal fusion, accompanying interbody fusion procedures, for treating lumbar degenerative spinal stenosis. This study focused on the optimal dose for each segment and the efficacy of E.BMP-2 as a substitute for autogenous iliac bone graft.Ten patients were enrolled from January 2015 to December 2015, and underwent an additional posterolateral fusion procedure, with 2.5 mg of E.BMP-2 followed by decompression, transpedicular fixation, and interbody fusion. The mean follow-up period was 13.9 months, and regular radiological examinations were performed in every case. Clinical outcomes were measured with a visual analog scale for back pain (VAS-BP), and leg pain (VAS-LP) and the Korean Oswestry Disability Index (K-ODI). All parameters were assessed preoperatively and postoperatively at 12 months.All 18 segments treated with E.BMP-2 completely fused in 6 months as observed on both simple radiography and computed tomography. The mean fusion period was 4.5 months on simple radiography. At 12 months follow-up, VAS-BP, VAS-LP, and K-ODI scores (1.9 ± 1.5, 1.9 ± 1.9, 11.0 ± 6.6, respectively) had improved significantly compared to preoperative scores (5.5 ± 1.9, 6.5 ± 1.9, and 49.9 ± 11.5, respectively, P < .05). There were no postoperative wound infections, neurological symptoms, or complications associated with the use of E.BMP-2 during the follow-up period.E.BMP-2 could be used to enhance the outcomes in posterolateral spinal fusion following interbody fusion surgery. In the present study, 2.5 mg of the E.BMP-2 per segment was sufficient to obtain bony union in posterolateral fusion surgery. Further large-scale trials with long-term follow-up are necessary to evaluate the various complications related to the use of E.BMP-2.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures
Similar articles
-
Effectiveness and Feasibility of Injectable Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 for Anterior Lumbar Interbody Fusion at the Lumbosacral Junction in Adult Spinal Deformity Surgery: A Clinical Pilot Study.Orthop Surg. 2022 Jul;14(7):1350-1358. doi: 10.1111/os.13303. Epub 2022 May 27. Orthop Surg. 2022. PMID: 35633034 Free PMC article. Clinical Trial.
-
Efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in additional lumbar posterolateral fusion: minimum 1-year follow-up.Spine J. 2021 Aug;21(8):1340-1346. doi: 10.1016/j.spinee.2021.04.007. Epub 2021 Apr 11. Spine J. 2021. PMID: 33848691
-
Minimally invasive lateral interbody fusion for the treatment of rostral adjacent-segment lumbar degenerative stenosis without supplemental pedicle screw fixation.J Neurosurg Spine. 2014 Dec;21(6):861-6. doi: 10.3171/2014.8.SPINE13841. Epub 2014 Oct 10. J Neurosurg Spine. 2014. PMID: 25303619
-
The minimally effective dose of bone morphogenetic protein in posterior lumbar interbody fusion: a systematic review and meta-analysis.Spine J. 2020 Aug;20(8):1286-1304. doi: 10.1016/j.spinee.2020.04.012. Epub 2020 Apr 24. Spine J. 2020. PMID: 32339767 Review.
-
Osteobiologies for Spinal Fusion from Biological Mechanisms to Clinical Applications: A Narrative Review.Int J Mol Sci. 2023 Dec 11;24(24):17365. doi: 10.3390/ijms242417365. Int J Mol Sci. 2023. PMID: 38139194 Free PMC article. Review.
Cited by
-
Anterior Cervical Discectomy and Fusion Using Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2: A Pilot Study.Clin Orthop Surg. 2022 Dec;14(4):557-563. doi: 10.4055/cios22032. Epub 2022 Sep 28. Clin Orthop Surg. 2022. PMID: 36518942 Free PMC article.
-
Effectiveness and Feasibility of Injectable Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 for Anterior Lumbar Interbody Fusion at the Lumbosacral Junction in Adult Spinal Deformity Surgery: A Clinical Pilot Study.Orthop Surg. 2022 Jul;14(7):1350-1358. doi: 10.1111/os.13303. Epub 2022 May 27. Orthop Surg. 2022. PMID: 35633034 Free PMC article. Clinical Trial.
References
-
- Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma 1989;3:192–5. - PubMed
-
- Summers BN, Eisenstein SM. Donor site pain from the ilium. A complication of lumbar spine fusion. J Bone Joint Surg Br 1989;71:677–80. - PubMed
-
- Urist MR, Dawson E. Intertransverse process fusion with the aid of chemosterilized autolyzed antigen-extracted allogeneic (AAA) bone. Clin Orthop Relat Res 1981;((154)):97–113. - PubMed
-
- Urist MR. Bone: formation by autoinduction. 1965. Clin Orthop Relat Res 2002;4–10. - PubMed
-
- Boden SD, Schimandle JH, Hutton WC. Lumbar intertransverse-process spinal arthrodesis with use of a bovine bone-derived osteoinductive protein. A preliminary report. J Bone Joint Surg Am 1995;77:1404–17. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical